natgillin/translations-raw huggingface dataset:
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati samo hidroklorotiazidom ili irbesartanom u dozi od 150 mg;
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2775 na drugoj strani.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg tablets.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets are peach, biconvex, oval- shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2876 na drugoj strani.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg filmom obložene tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati irbesartanom u dozi od 300 mg ili lijekom Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2776 na drugoj strani.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets are pink, biconvex, oval- shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2788 na drugoj strani.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložene tablete
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati lijekom Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg tablets irbesartan/hydrochlorothiazide
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg tablete irbesartan/hidroklorotiazid
Irbesartan Hydrochlorothiazide Zentiva can be taken with or without food.
Irbesartan Hydrochlorothiazide Zentiva se može uzeti s hranom ili bez nje.
Irbesartan Hydrochlorothiazide Zentiva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Irbesartan Hydrochlorothiazide Zentiva je kombinacija irbesartana, antagonista receptora angiotenzina II i hidroklorotiazida, tiazidskog diuretika.
Irbesartan Hydrochlorothiazide Zentiva should not be given to children under 18 years of age.
Irbesartan Hydrochlorothiazide Zentiva ne smiju uzimati djeca mlađa od 18 godina.
Irbesartan Hydrochlorothiazide Zentiva should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Irbesartan Hydrochlorothiazide Zentiva ne smiju uzimati bolesnici s teško oštećenom funkcijom bubrega (klirens kreatinina <30 ml/min) (vidjeti dio 4.3).
Irbesartan Hydrochlorothiazide Zentiva with food and drink
Irbesartan Hydrochlorothiazide Zentiva s hranom i pićem
Irbesartan Hydrochlorothiazide Zentiva1 irbesartan / hydrochlorothiazide
Irbesartan Hydrochlorothiazide Zentiva1 irbesartan/hidroklorotiazid
Irbesartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Irbesartan je „antagonist receptora angiotenzina II”, što znači da blokira djelovanje hormona angiotenzina II u tijelu.
Irbesartan is an ‘angiotensin II receptor antagonist’, which means that it blocks the action of a hormone in the body called angiotensin II.
Irbesartan je „antagonist receptora angiotenzina II”, što znači da blokira rad hormona angiotenzina II u tijelu.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all- cause mortality.
Irbesartan značajno snižava relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručavanja serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause mortality.
Irbesartan značajno snižava relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručenog serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 and 56 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-peroforated calendar blisters.
Irbesartan Teva dostupan je u pakiranjima sa 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 i 100 filmom obloženih tableta u neperforiranim blisterima; pakiranjima sa 50 x 1 i 56 x 1 filmom obloženom tabletom u blisterima djeljivim na jedinične doze i pakiranju sa 28 filmom obloženih tableta u neperforiranim kalendarskim blisterima.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters and pack size of 28 fim-coated tablets in non-perforated calendar blisters.
Irbesartan Teva dostupan je u pakiranjima sa 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 i 100 filmom obloženih tableta u neperforiranim blisterima; pakiranjima sa 50 x 1 i 56 x 1 filmom obloženom tabletom u blisterima djeljivim na jedinične doze i pakovanju sa 28 filmom obloženih tableta u neperforiranim kalendarskim blisterima.
Irbesartan Teva is available in pack sizes of 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizies of 50 x 1 and 56 x 1 film-coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters..
Irbesartan Teva dostupan je u pakiranjima sa 7, 14, 28, 30, 56, 60, 80, 84, 90, 98 i 100 filmom obloženih tableta u neperforiranim blisterima; pakovanjima sa 50 x 1 i 56 x 1 filmom obloženom tabletom u blisterima djeljivim na jedinične doze i pakiranju sa 28 filmom obloženih tableta u neperforiranim kalendarskim blisterima.
Irbesartan Teva is for oral use.
Irbesartan Teva je namijenjen za primjenu kroz usta.
Irbesartan Teva is indicated in adults for the treatment of essential hypertension.
Irbesartan Teva je indiciran za liječ enje esencijalne hipertenzije u odraslih.
Irbesartan Teva is indicated in adults for the treatment of essential hypertension.
Irbesartan Teva je indiciran za liječ enje esencijalne hipertenzije u odrslih.
Irbesartan Teva is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Irbesartan Teva ne preporučuje se u ranoj trudnoći te se ne smije uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu, uzimate li ga u tom razdoblju.
Irbesartan Teva is used in adult patients
Irbesartan Teva primjenjuje se u odraslih bolesnika za
Irbesartan Zentiva 150 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side.
Irbesartan Zentiva 150 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2872 na drugoj strani.
Irbesartan Zentiva 150 mg film-coated tablets.
Irbesartan Zentiva 150 mg filmom obložene tablete
Irbesartan Zentiva 150 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side.
Irbesartan Zentiva 150 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2772 na drugoj strani.
Irbesartan Zentiva 150 mg tablets irbesartan
Irbesartan Zentiva 150 mg tablete irbesartan
Irbesartan Zentiva 150 mg tablets.
Irbesartan Zentiva 150 mg tablete
Irbesartan Zentiva 300 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side.
Irbesartan Zentiva 300 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2873 na drugoj strani.
Irbesartan Zentiva 300 mg film-coated tablets.
Irbesartan Zentiva 300 mg filmom obložene tablete
Irbesartan Zentiva 300 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side.
Irbesartan Zentiva 300 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2773 na drugoj strani.
Irbesartan Zentiva 300 mg tablets irbesartan
Irbesartan Zentiva 300 mg tablete irbesartan
Irbesartan Zentiva 300 mg tablets.
Irbesartan Zentiva 300 mg tablete
Irbesartan Zentiva 75 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side.
Irbesartan Zentiva 75 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2871 na drugoj strani.
Irbesartan Zentiva 75 mg film-coated tablets.
Irbesartan Zentiva 75 mg filmom obložene tablete
Irbesartan Zentiva 75 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side.
Irbesartan Zentiva 75 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2771 na drugoj strani.
Irbesartan Zentiva 75 mg tablets irbesartan
Irbesartan Zentiva 75 mg tablete irbesartan
Irbesartan Zentiva 75 mg tablets.
Irbesartan Zentiva 75 mg tablete
Irbesartan Zentiva can be taken with or without food.
Irbesartan Zentiva se može uzeti s hranom ili bez nje.
Irbesartan Zentiva in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
U kombinaciji s lijekovima koji sadrže aliskiren (koristi se za liječenje esencijalne hipertenzije) Irbesartan Zentiva ne smije se koristiti u bolesnika s dijabetesom, ili umjerenim do ozbiljnim oštećenjem funkcije bubrega.
Irbesartan Zentiva is also used to treat kidney disease in adults with hypertension and type 2 diabetes.
Irbesartan Zentiva se također koristi za liječenje bolesti bubrega u odraslih s hipertenzijom i šećernom bolešću tipa 2.
Irbesartan Zentiva is used in adult patients
Irbesartan Zentiva se primjenjuje u odraslih bolesnika za
Irbesartan Zentiva was used for two years or more.
Irbesartan Zentiva se primjenjivao tijekom dvije godine ili duže.
Irbesartan Zentiva with food and drink
Irbesartan Zentiva s hranom i pićem
Irbesartan/hydrochlorothiazide combination:
Irbesartan/hidroklorotiazid u kombinaciji:
Irbesartan/Hydrochlorothiazide Teva
Irbesartan/Hidroklorotiazid Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets
Irbesartan/Hidroklorotiazid Teva 150 mg/12,5 mg filmom obložene tablete
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hidroklorotiazid Teva 150 mg/12,5 mg filmom obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Irbesartan/Hidroklorotiazid Teva 150 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati samo hidroklorotiazidom ili irbesartanom u dozi od 150 mg;
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets
Irbesartan/Hidroklorotiazid Teva 300 mg/12,5 mg filmom obložene tablete
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets are light pink to pink, film coated capsule shaped tablets.
Irbesartan/Hidroklorotiazid Teva 300 mg/12,5 mg filmom obložene tablete su svijetlo ružičaste do ružičaste filmom obložene tablete u obliku kapsula.
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hidroklorotiazid Teva 300 mg/12,5 mg filmom obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg.
Irbesartan/Hidroklorotiazid Teva 300 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati irbesartanom u dozi od 300 mg ili lijekom Irbesartan/Hidroklorotiazid Teva 150 mg/12,5 mg.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets are pink to dark pink, film coated capsule shaped tablet.
Irbesartan/Hidroklorotiazid Teva 300 mg/25 mg filmom obložene tablete su ružičaste do tamnoružičaste filmom obložene tablete u obliku kapsula.
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan / hydrochlorothiazide
Irbesartan/Hidroklorotiazid Teva 300 mg/25 mg filmom obložene tablete irbesartan / hidroklorotiazid
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg.
Irbesartan/Hidroklorotiazid Teva 300 mg/25 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati lijekom Irbesartan/Hidroklorotiazid Teva 300 mg/12,5 mg.
Irbesartan/Hydrochlorothiazide Teva can be taken once daily, with or without food.
Irbesartan/Hidroklorotiazid Teva može se uzimati jedanput na dan, s hranom ili bez nje.
Irbesartan/Hydrochlorothiazide Teva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Irbesartan/Hidroklorotiazid Teva je kombinacija irbesartana, antagonista receptora angiotenzina II i hidroklorotiazida, tiazidskog diuretika.
Irbesartan/Hydrochlorothiazide Teva is a combination of two active substances, irbesartan and hydrochlorothiazide.
Irbesartan/Hidroklorotiazid Teva je kombinacija dvije djelatne tvari, irbesartana i hidroklorotiazida.
Irbesartan/Hydrochlorothiazide Teva is a medicine that contains two active substances, irbesartan and hydrochlorothiazide.
Irbesartan/Hidroklorotiazid Teva je lijek koji sadrži dvije djelatne tvari, irbesartan i hidroklorotiazid.
Irbesartan/Hydrochlorothiazide Teva is a ‘generic medicine’.
Irbesartan/Hidroklorotiazid Teva „generički je lijek”.
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Irbesartan/Hidroklorotiazid Teva dostupan je u pakiranjima od 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 i 100 filmom obloženih tableta u neperforiranim blisterima; pakiranje od 50 x 1 filmom obloženom tabletom u blisterima djeljivi na jedinične doze i pakiranje od 28 filmom obloženih tableta u neperforiranim blisterima u kalendarskom pakiranju.
Irbesartan/Hydrochlorothiazide Teva is for oral use.
Irbesartan/Hidroklorotiazid Teva namijenjen je za primjenu kroz usta.
Irbesartan/Hydrochlorothiazide Teva is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Irbesartan/Hidroklorotiazid Teva ne preporučuje se majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
Irbesartan/Hydrochlorothiazide Teva is unlikely to affect your ability to drive or use machines.
Irbesartan/Hidroklorotiazid Teva ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima i strojevima.
Irbesartan/Hydrochlorothiazide Teva should be taken at least one hour before or four hours after these medications;
Irbesartan/Hidroklorotiazid Teva se mora uzeti najmanje jedan sat prije ili 4 sata poslije tih lijekova;
Irbesartan/Hydrochlorothiazide Teva should not be given to children and adolescents (under 18 years).
Irbesartan/Hidroklorotiazid Teva se ne smije davati djeci i adolescentima (mlađima od 18 godina).
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Irbesartan/hidroklorotiazid: potencijalna toksičnost kombinacije irbesartan/hidroklorotiazid nakon oralne primjene ocijenjena je na štakorima i makaki majmunima, u studijama koje su trajale do 6 mjeseci.
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Irbesartan/hidroklorotiazid: potencijalna toksičnost kombinacije irbesartan/hidroklorotiazid nakon peroralne primjene ocijenjena je na štakorima i makaki majmunima, u ispitivanjima koja su trajala do 6 mjeseci.
Irbesartan/hydrochlorothiazide: the potential toxicity of the irbesartan/hydrochlorothiazide combination after oral administration was evaluated in rats and macaques in studies lasting up to 6 months.
Irbesartan/hidroklorotiazid: potencijalna toksičnost kombinacije irbesartan/hidroklorotiazid nakon peroralne primjene ocijenjena je na štakorima i makaki majmunima, u istraživanjima koja su trajala do 6 mjeseci.
Irbesartan/Hydrocholorthiazide Teva 300 mg/25 mg film-coated tablets
Irbesartan/Hidroklorotiazid Teva 300 mg/25 mg filmom obložene tablete
Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses.
Irbesartan: nije bilo znakova abnormalne sistemske toksičnosti ili toksičnosti za ciljni organ pri klinički relevantnim dozama.
IRC evaluated, median follow--up 18.4 months;
procijenjeno prema IRC-u, medijan praćenja 18,4 mjeseci;
IRC-assessed PFS (PFS-IRC)
PFS prema ocjeni neovisnog ocjenjivačkog povjerenstva
IRC-assessed PFS (PFS-IRC)a
PFS prema ocjeni neovisnog ocjenjivačkog povjerenstvaa
IRC-Assessed Primary and Subgroup Analyses of PFS, Months
Primarna analiza PFS-a i analiza PFS-a po podskupinama prema ocjeni neovisnog ocjenjivačkog povjerenstva, mjeseci
IRC-assessed progression-free survival (PFS)
Preživljenje bez progresije bolesti (PFS) prema procjeni neovisnog ocjenjivačkog povjerenstva (IRC)
IRC-Assessed Secondary Outcome
Sekundarna mjera ishoda prema ocjeni neovisnog ocjenjivačkog povjerenstva
Ire land medac GmbH
Ireland medac GmbH
Ireland
0164 Oslo
Ireland
Cork Irska
Ireland
County Cork Irska
Ireland
Dublin 13 Irska
Ireland
Irska‌‌
Ireland and
Galway, Irska i
Ireland‌
Irska
IRESSA contains the active substance gefitinib which blocks a protein called ‘epidermal growth factor receptor’ (EGFR).
IRESSA sadrži djelatnu tvar gefitinib koja blokira protein zvan „receptor epidermalnog faktora rasta“ (EGFR, prema engl. epidermal growth factor receptor).
IRESSA is a round brown tablet marked with ‘IRESSA 250’ on one side and plain on the other.
IRESSA tableta je okrugla i smeđa, s utisnutom oznakom "IRESSA 250" na jednoj i bez oznaka na drugoj strani.
IRESSA is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (see section 4.4).
IRESSA je indicirana za liječenje odraslih bolesnika s lokalno uznapredovalim ili metastatskim rakom pluća ne-malih stanica (non-small cell lung cancer, NSCLC) s aktivirajućim mutacijama tirozin kinaze receptora epidermalnog faktora rasta (epidermal growth factor receptor, EGFR-TK) (vidjeti dio 4.4).
IRESSA is not indicated in children and adolescents under 18 years.
IRESSA nije namijenjena za primjenu u djece i adolescenata mlađih od 18 godina.
IRF-Assessed laBCC** (n  63)
Prema procjeni neovisnog ocjenjivačkog tijela
iridocyclitis, eye inflammation, photopsia, eczema eyelids, conjunctival oedema, halo vision, conjunctival follicles, hypoaesthesia eye, meibomianitis, anterior chamber pigmentation, mydriasis, eyelash thickening
iridociklitis, upala oka, fotopsija, ekcem vjeđa, konjunktivalni edem, pojava obojenih ili svjetlećih krugova oko izvora svjetlosti, konjunkitvalni folikuli, hipoestezija oka, meibomianitis, pigmentacija prednje očne sobice, midrijaza, zadebljanje trepavica
Irinotecan
irinotekan
Irinotecan
Irinotekan:
irinotecan (used to treat cancer)
irinotekan (primjenjuje se u liječenju raka)
Irinotecan belongs to a group of cancer medicines called ‘topoisomerase inhibitors’.
Irinotekan spada u skupinu lijekova protiv raka pod nazivom ‘inhibitori topoizomeraze’.
Irinotecan dose should be reduced by 15-20% in subsequent cycles.
U sljedećim ciklusima treba smanjiti dozu irinotekana za 15-20%.
Irinotecan dose should be reduced by 15-20%.
Treba smanjiti dozu irinotekana za 15-20%.
irinotecan due to an alteration of the metabolism of this medicinal product
irinotekan zbog izmjene metabolizma ovog lijeka
Irinotecan, a chemotherapy drug used to treat cancer of the colon and rectum.
irinotekanom – koristi se u kemoterapiji kod liječenja karcinoma debelog crijeva i završnog dijela debelog crijeva (rektuma).
irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer)
irinotekan, dasatinib, nilotinib, vinblastin i vinkristin (primjenjuju se za liječenje raka)
irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
irinotekan, etopozid, vinorelbin, ifosfamid (lijekovi za liječenje raka),
irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),
irinotekan, etopozid, vinorelbin, ifosfamid (za liječenje karcinoma),
Irinotecan: AUC: ↑ 2.1-fold
AUC: ↑ 2,1 puta
Iris color changes seen with ophthalmic administration of bimatoprost may not be noticeable for several months to years.
Promjena boje šarenice zbog oftalmičke primjene bimatoprosta može ostati neprimjetna nekoliko mjeseci do nekoliko godina.
Iris disorder,
poremećaj mrežnice,
Iris disorder,
poremećaj šarenice,
Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctival hyperaemia Eye irritation,
edem oka, oticanje oka, poremećaj oka, konjuktivalna hiperemija, iritacija oka, neuobičajena
Iris inflammation
Upala šarenice
iritis, conjunctival oedema,
iritis, edem konjunktive, bol vjeđa,
iritis, conjunctival oedema, eyelid pain, visual acuity worsened, trichiasis, iris hyperpigmentation, deepening of eyelid sulcus, eyelid retraction
iritis, edem konjunktive, bol vjeđa, pogoršanje oštrine vida, trihijaza, hiperpigmentacija šarenice, produbljenje palpebralnog sulkusa, retrakcija vjeđe
IRL-Dublin 15
Blanchardstown IRL-Dublin 15